drugset / Trial / NCT07570654
Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The Redefine Study (COMP202) is testing COMP360 to see if it may reduce post-traumatic stress disorder (PTSD) symptoms when administered alongside monitoring and support from a trained study team. COMP360 is a lab-made form of the naturally occurring chemical compound psilocybin.
Timeline
- Start
- 2026-09
- Primary completion
- 2028-11
- Completion
- 2029-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Psilocybin | Other / unclassified | 1 mg | — |
| Subject | Psilocybin | Other / unclassified | 10 mg | — |
| Subject | Psilocybin | Other / unclassified | 25 mg | — |